DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Inpatient Drug Tracking

Formerly known as AMR, our Inpatient Drug Tracking provides a comprehensive analysis and tracking solution.

 

For pharma companies, there is a major challenge to quantify the quality outcomes of drugs. For many providers, there are new quality measures that will require tracking. Our platforms provide a comprehensive analysis and tracking solution for both.

Already a User?

Access our inpatient drug tracking platforms here:

China RXHospital Market Guides


Drug Tracking in the United States and Europe

Our databases offer comprehensive and detailed audits of inpatient clinical usage for the most commercially relevant therapies.

Our inpatient drug tracking in the United States and Europe allows users to fully understand market shares and customer practice patterns with timely and detailed data that goes beyond sales. Track performance against competitors via global market size and growth analyses, and detect utilization shifts with deep analysis of clinical procedures and trends.


Antibiotic Market Guide

Antifungal Market Guide

Download our brochures to learn more about the breadth of coverage


 


Drug Tracking in China

China represents a $120 billion pharmaceutical market: the second largest in the world, with a projected 15% annual growth rate.

China Rx Database

Gain the in-depth data and analytics you need for success in this lucrative Chinese pharmaceutical market with the China Rx Database. Dive deeply into current and emerging treatment patterns, pricing and reimbursement, and physician sentiment. Review drug sale roll-ups across major therapeutic areas. China Rx answers crucial market outlook and brand performance questions.

  • What are manufacturers’ revenues across diseases in China?
  • Where are the opportunities within a treatment algorithm of a disease?
  • How does patient profile and diagnosed incidence case change by disease?
  • How do the sales of a drug differ across diseases?
  • What are physician diagnosis patterns?
  • What are the drug shares within each disease?
  • What are the generic and branded revenues of a drug by disease?
  • What is the drug pricing and reimbursement status?
  • What are the major market events, including emerging treatment options?

 

Our latest thoughts and commentary

 

Latest articles

JAK inhibitors in IBD

On the Way to Becoming JAKs of All Trades On July 13th, 2017 Pfizer announced that its application for approval in ulcerative...

More Articles

In the news
News articles citing DRG analysts data.
More News